NVAX Q4 2023 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$291M+1.2% YoY

Gross Profit

$142M48.9% margin

Operating Income

-$184M-63.0% margin

Net Income

-$178M-61.2% margin

EPS (Diluted)

$-1.44

QoQ Revenue Growth

+1220.4%

Cash Flow

Operating Cash Flow

-$177M

Free Cash Flow

-$186M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$2.5B

Stockholders' Equity

-$717M

Cash & Equivalents

$569M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$291M	$288M	+1.2%
Gross Profit	$142M	$106M	+34.3%
Operating Income	-$184M	-$244M	+24.7%
Net Income	-$178M	-$182M	+2.1%

Revenue Segments

Product

$251M86%

Grant

$38M13%

Royalties and Other

$2M1%

Geographic Segments

Europe

$210M83%

North America

$28M11%

Rest of the World

$14M6%